D. E. Shaw & Co. Inc. Sells 76,098 Shares of Core Laboratories Inc. (NYSE:CLB)

D. E. Shaw & Co. Inc. lessened its holdings in Core Laboratories Inc. (NYSE:CLB) by 54.7% during the 4th quarter, according to its most recent filing with the Securities & Exchange Commission. The firm owned 63,082 shares of the oil and gas company’s stock after selling 76,098 shares during the period. D. E. Shaw & Co. Inc. owned about 0.13% of Core Laboratories worth $1,092,000 at the end of the most recent reporting period.

Several other institutional investors have also recently made changes to their positions in the business. T. Rowe Price Investment Management Inc. raised its stake in Core Laboratories by 4.2% during the 4th quarter. T. Rowe Price Investment Management Inc. now owns 1,158,702 shares of the oil and gas company’s stock worth $20,058,000 after acquiring an additional 46,941 shares during the period. Geode Capital Management LLC raised its stake in Core Laboratories by 0.5% during the 4th quarter. Geode Capital Management LLC now owns 1,058,620 shares of the oil and gas company’s stock worth $18,329,000 after acquiring an additional 5,416 shares during the period. Dimensional Fund Advisors LP raised its stake in Core Laboratories by 3.5% during the 4th quarter. Dimensional Fund Advisors LP now owns 847,983 shares of the oil and gas company’s stock worth $14,678,000 after acquiring an additional 28,393 shares during the period. Boston Trust Walden Corp raised its stake in Core Laboratories by 2.7% during the 4th quarter. Boston Trust Walden Corp now owns 617,336 shares of the oil and gas company’s stock worth $10,686,000 after acquiring an additional 16,503 shares during the period. Finally, Northern Trust Corp raised its stake in Core Laboratories by 15.6% during the 4th quarter. Northern Trust Corp now owns 577,752 shares of the oil and gas company’s stock worth $10,001,000 after acquiring an additional 78,173 shares during the period. Institutional investors own 97.81% of the company’s stock.

Core Laboratories Stock Performance

Shares of Core Laboratories stock opened at $10.88 on Friday. The company has a market capitalization of $509.85 million, a PE ratio of 16.48, a P/E/G ratio of 0.99 and a beta of 1.45. The company has a debt-to-equity ratio of 0.49, a quick ratio of 1.71 and a current ratio of 2.32. The company has a 50-day simple moving average of $12.62 and a two-hundred day simple moving average of $16.20. Core Laboratories Inc. has a one year low of $10.14 and a one year high of $25.13.

Core Laboratories (NYSE:CLB) last posted its quarterly earnings data on Wednesday, April 23rd. The oil and gas company reported $0.14 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.15 by ($0.01). Core Laboratories had a net margin of 5.99% and a return on equity of 16.24%. The company had revenue of $123.59 million for the quarter, compared to analyst estimates of $125.09 million. During the same quarter last year, the company earned $0.19 EPS. The business’s revenue was down 4.7% compared to the same quarter last year. Research analysts expect that Core Laboratories Inc. will post 0.96 EPS for the current fiscal year.

Core Laboratories Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Tuesday, May 27th. Shareholders of record on Monday, May 5th will be given a $0.01 dividend. The ex-dividend date is Monday, May 5th. This represents a $0.04 dividend on an annualized basis and a dividend yield of 0.37%. Core Laboratories’s dividend payout ratio (DPR) is currently 6.78%.

Analysts Set New Price Targets

A number of equities research analysts have issued reports on CLB shares. Wall Street Zen lowered shares of Core Laboratories from a “hold” rating to a “sell” rating in a report on Friday, April 25th. Stifel Nicolaus cut their target price on shares of Core Laboratories from $19.00 to $15.00 and set a “hold” rating for the company in a report on Tuesday, April 15th. Finally, Citigroup cut their target price on shares of Core Laboratories from $16.00 to $13.00 and set a “neutral” rating for the company in a report on Tuesday, May 13th. Two investment analysts have rated the stock with a sell rating and three have given a hold rating to the company’s stock. According to data from MarketBeat.com, Core Laboratories presently has a consensus rating of “Hold” and an average target price of $15.00.

Core Laboratories Company Profile

Core Laboratories Inc provides reservoir description and production enhancement services and products to the oil and gas industry in the United States, and internationally. It operates through Reservoir Description and Production Enhancement segments. The Reservoir Description segment includes the characterization of petroleum reservoir rock and reservoir fluid samples to enhance production and improve recovery of crude oil and gas from its clients' reservoirs.